ArticleEuropean journal of nuclear medicine and molecular imaging2018
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial.Molecular imaging and biology · 2020Trial
- Relationship between [European radiology · 2025Article
- A Case of Diffuse Infiltrative Hepatocellular Carcinoma with Marked Response to Sorafenib Treatment Evidenced byMolecular imaging and radionuclide therapy · 2024Article
- Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.American journal of cancer research · 2024Article
- Article
- Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study.Journal of clinical medicine · 2021Article
- Article
- A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.Journal of clinical medicine · 2020Article
- Noninvasive Imaging for Assessment of the Efficacy of Therapeutic Agents for Hepatocellular Carcinoma.Molecular imaging and biology · 2020Review
- Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma.Journal of liver cancer · 2020Article
- Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology.Medicina (Kaunas, Lithuania) · 2020Review
- Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis.Liver cancer · 2020Article
- Hypoxia-induced modulation of glucose transporter expression impactsEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Article
- Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection.Frontiers in oncology · 2020Article
- Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy.Frontiers in oncology · 2020Article
- Relationship between PD-L1 expression andAging · 2019Article
- Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma.International journal of clinical oncology · 2019Article
- Relationship between the expression of PD-1/PD-L1 andEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Emerging role ofWorld journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
purposeSorafenib, an oral multikinase inhibitor, is a recommended treatment option available for patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC). This study aimed to evaluate the performance of
methodsWe formed a retrospective cohort comprising patients treated with sorafenib for at least 30 days and undergoing
resultsAmong a total of 35 patients, two obtained partial remission, and 11 showed stable disease after the first response evaluation. Patients with a TLR ≥ 2.9 (n = 17) had a median overall survival (OS) of 3.7 months after sorafenib treatment, whereas patients with a TLR < 2.9 (n = 18) had median OS of 12.2 months (P < 0.001), although the disease control rate was not significantly different between the two groups. Pretreatment TLR ≥ 2.9 (hazard ratio [HR] = 6.318, P = 0.002) and Child-Pugh class B (HR = 4.316, P = 0.044) were poor prognostic factors for OS, and a TLR ≥ 2.9 (HR = 2.911, P = 0.024) was the only poor prognostic factor for progression-free survival in a multivariate analysis.
conclusionPretreatment tumour metabolic activity assessed by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.